Goldman Sachs
TERN

Goldman Sachs’s Terns Pharmaceuticals TERN Stock Holding History

Goldman Sachs’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.4M Buy
1,106,961
+43,977
+4% +$1.81M 0.01% 1458
2025
Q4 		$42.9M Buy
1,062,984
+516,155
+94% +$11.9M 0.01% 1636
2025
Q3 		$4.11M Buy
546,829
+220,596
+68% +$1.41M ﹤0.01% 3829
2025
Q2 		$1.22M Sell
326,233
-88,788
-21% -$277K ﹤0.01% 4547
2025
Q1 		$1.15M Buy
415,021
+71,971
+21% +$294K ﹤0.01% 4583
2024
Q4 		$1.9M Sell
343,050
-75,817
-18% -$513K ﹤0.01% 4325
2024
Q3 		$3.49M Sell
418,867
-279,847
-40% -$2.3M ﹤0.01% 3673
2024
Q2 		$4.76M Buy
698,714
+491,728
+238% +$2.98M ﹤0.01% 3198
2024
Q1 		$1.36M Buy
206,986
+121,395
+142% +$793K ﹤0.01% 4140
2023
Q4 		$555K Sell
85,591
-173,705
-67% -$918K ﹤0.01% 4695
2023
Q3 		$1.3M Buy
259,296
+201,514
+349% +$1.28M ﹤0.01% 4081
2023
Q2 		$506K Sell
57,782
-31,522
-35% -$367K ﹤0.01% 4740
2023
Q1 		$1.06M Buy
89,304
+78,474
+725% +$750K ﹤0.01% 4342
2022
Q4 		$110K Sell
10,830
-1,086
-9% -$7.23K ﹤0.01% 5457
2022
Q3 		$70K Sell
11,916
-4,672
-28% -$17.4K ﹤0.01% 5759
2022
Q2 		$41K Buy
16,588
+161
+1% +$322 ﹤0.01% 6067
2022
Q1 		$49K Buy
16,427
+1,219
+8% +$5.2K ﹤0.01% 6276
2021
Q4 		$108K Buy
+15,208
New +$127K ﹤0.01% 6109

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Goldman Sachs's TERN Position: Q1 2026 in Review

Goldman Sachs increased its Terns Pharmaceuticals (TERN) stake by 4.1% in Q1 2026, buying an estimated $1.81M and bringing the position to 1,106,961 shares worth $58.4M. The position accounts for 0.01% of the portfolio, ranked #1458.

Goldman Sachs first reported a position in TERN in Q4 2021 and has held it in 18 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Goldman Sachs held 1,106,961 shares of Terns Pharmaceuticals worth $58.4M as of Q1 2026.
  • Goldman Sachs bought 43,977 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.81M.
  • Terns Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1458 holding.
  • Goldman Sachs first reported a position in Terns Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.